Highest-materiality recent filing
GeneDx Q1 revenue $102.3M (+17% YoY); exome/genome volume +34%; FY guidance $475-490M
Q1 revenue $102.3M (+17% YoY); exome/genome revenue $90.6M (+27% YoY).
GeneDx enters $100M term loan with Blackstone to repay existing credit facility
$100M term loan funded Feb 27, 2026; proceeds used to repay existing Perceptive Credit term loan.
GeneDx Q4 revenue $121M, +27% YoY; exome/genome +32%; reaffirms FY2026 guidance $540-555M
Q4 revenue $121M (+27% YoY); exome/genome revenue $104M (+32%, or +42% ex one-time).
GeneDx prelim FY2025 rev $427M (+41%); FY2026 guidance $540-555M
FY2025 exome/genome revenue ~$360M (+54% YoY); Q4 $104M (+32% YoY).
GeneDx Q3 2025 revenue $116.7M (+52% YoY), adjusted net income $14.7M; raises full-year guidance
Q3 revenue $116.7M (+52% YoY); exome/genome revenue $98.9M (+65% YoY).
GeneDx appoints Thomas Fuchs, SVP & Chief AI Officer at Lilly, as Class I director
Thomas Fuchs appointed to board effective September 17, 2025; board expands from 7 to 8 members.
GeneDx Q2 revenue $102.7M (+49% YoY); raises FY outlook to $400-415M
Exome/genome test revenue $85.9M (+69% YoY) on volume of 23,102 results (+28%).
GeneDx re-elects Casdin and Ruch as Class I directors; EY ratified as auditor
Eli D. Casdin re-elected with 16,013,641 votes for, 6,823,343 withheld.
GeneDx Q1 revenue $87.1M, exome/genome revenue up 62% YoY; raises FY 2025 guidance
Q1 exome/genome revenue $71.4M (+62% YoY); total revenue $87.1M (+42% YoY).
GeneDx to acquire Fabric Genomics for up to $51M; expands AI genomic interpretation globally
GeneDx will pay $33M cash at closing for Fabric Genomics; total consideration up to $51M based on milestone achievements (2025/2026 revenue and margin targets).
GeneDx Q4 revenue up 64% YoY to $95.3M; adjusted net income $16.8M; FY2025 guidance $350-360M
Q4 revenues $95.3M (+64% YoY); exome/genome revenue $78.8M (+101% YoY).
GeneDx reports prelim FY2024 revenue ≥$299M (+54% YoY), above prior guidance
Preliminary FY2024 revenue at least $299M (+54% YoY), above prior guidance of $284-290M.
GeneDx appoints Bryan Dechairo as COO with $450K salary and $2.7M RSU award
Bryan Dechairo appointed COO effective Jan 2, 2025; reports to CEO Katherine Stueland.
GeneDx achieves Q3 2024 profitability with $1.2M adjusted net income, raises FY guidance
Revenue $76.6M (+52% YoY); exome/genome revenue $60.0M (+77% YoY).
GeneDx Q2 revenue $68.9M (+52% YoY); raises FY24 revenue guidance to $255-265M
Exome/genome test revenue $50.7M (+77% YoY), volume 18,017 (+52% YoY).
GeneDx stockholders elect three Class III directors and ratify EY as auditor
Emily Leproust, Keith Meister, and Richard Pfenniger Jr. elected as Class III directors with over 17M votes for each.
On January 2, 2025, GeneDx Holdings Corp. (the “Company”) announced the appointment of Bryan Dechairo, Ph.D., age 52, in the newly created role of Chief Operating Officer, effective immediately.
Max materiality 0.85 · Median 0.75 · Most common event earnings